Pfizer beat the expectation even though it fell short on revenue

By: Miguel A. Rodriguez

09:45, 14 September 2020

Although it is in the race of developing a vaccine, Pfizer’s stock price fell in the first half of the year

For pharmaceutical giant Pfizer, the past quarter was busy as it is working on developing a COVID-19 vaccine, and the financial results that came in beat the expectations.

The net income fell for Q2 to $3.43 billion, meaning an EPS of 61 cents. During the same time last year, Pfizer had an EPS of 89 cents, and a net income of $5.05 billion.

It lost 11% on revenue, figures coming in at $11.80 billion, but it beat the $11.58 billion consensus. 

Pfizer provided guidance for the rest of the year. The EPS was adjusted to $2.85 with a $2.95 high from a previous $2.82 to $2.92. The revenue is expected to reach a high of $50.5 billion downgrading from an initial top of $50.6 billion.

During today’s pre-market session, the stock price gained 3.4%. Since the beginning of 2020, the share price fell 4.2%, while USA30 lost 6.9%.  


Share this article

This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided.